Gamco Investors INC. ET AL Takes $3.61 Million Position in Pharmerica Corporation (PMC)

Gamco Investors INC. ET AL bought a new stake in shares of Pharmerica Corporation (NYSE:PMC) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 123,351 shares of the company’s stock, valued at approximately $3,614,000. Gamco Investors INC. ET AL owned approximately 0.40% of Pharmerica Corporation at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Shell Asset Management Co. bought a new stake in shares of Pharmerica Corporation during the 3rd quarter valued at $1,946,000. Chicago Equity Partners LLC bought a new stake in shares of Pharmerica Corporation during the 2nd quarter valued at $2,061,000. Victory Capital Management Inc. boosted its holdings in shares of Pharmerica Corporation by 40.1% during the 2nd quarter. Victory Capital Management Inc. now owns 1,294,142 shares of the company’s stock valued at $33,971,000 after buying an additional 370,266 shares in the last quarter. Peregrine Capital Management LLC boosted its holdings in shares of Pharmerica Corporation by 2.0% during the 2nd quarter. Peregrine Capital Management LLC now owns 430,934 shares of the company’s stock valued at $11,312,000 after buying an additional 8,615 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Pharmerica Corporation by 4.5% during the 1st quarter. Geode Capital Management LLC now owns 429,851 shares of the company’s stock valued at $10,058,000 after buying an additional 18,452 shares in the last quarter. Hedge funds and other institutional investors own 86.49% of the company’s stock.

Pharmerica Corporation (NYSE PMC) opened at C$29.10 on Monday. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.58 and a quick ratio of 1.79. The stock has a market capitalization of $905.60, a PE ratio of 15.08, a PEG ratio of 1.27 and a beta of 0.82. Pharmerica Corporation has a 52-week low of C$22.00 and a 52-week high of C$29.50.

Pharmerica Corporation (NYSE:PMC) last posted its quarterly earnings results on Thursday, November 9th. The company reported C$0.46 earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.49 by C($0.03). The company had revenue of C$595.10 million during the quarter, compared to analysts’ expectations of C$596.80 million. Pharmerica Corporation had a return on equity of 10.94% and a net margin of 0.83%. research analysts expect that Pharmerica Corporation will post 1.92 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This report was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/11/13/gamco-investors-inc-et-al-takes-3-61-million-position-in-pharmerica-corporation-pmc.html.

A number of analysts have recently commented on PMC shares. Zacks Investment Research cut shares of Pharmerica Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. BidaskClub cut shares of Pharmerica Corporation from a “hold” rating to a “sell” rating in a report on Monday, July 31st. KeyCorp cut shares of Pharmerica Corporation to an “overweight” rating in a report on Wednesday, August 2nd. Barrington Research cut shares of Pharmerica Corporation from an “outperform” rating to an “underperform” rating in a report on Thursday, August 3rd. Finally, UBS AG restated a “neutral” rating and set a $29.25 target price (up previously from $26.00) on shares of Pharmerica Corporation in a report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. Pharmerica Corporation currently has a consensus rating of “Hold” and a consensus price target of C$30.50.

Pharmerica Corporation Company Profile

Institutional Ownership by Quarter for Pharmerica Corporation (NYSE:PMC)

Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply